Please assess the completion status of the following clinical trial:

Trial Title: The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves Replacement

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient with tricuspid regurgitation and right heart failure after left heart valves replacement~2. Patients who takes existing diuretic~3. The patient is willing to participate in the study~Exclusion Criteria:~1. Patients with hypersensitivity to study drug~2. Anuric patients~3. Patients with hypernatremia~4. Female patients who are pregnant, possibly pregnant, or lactating, or who plan to become pregnant~5. Malignant tumor~6. Patients with serious hepatic disorder or Serious Renal failure~7. Patients otherwise judged by the investigator or subinvestigator to be inappropriate for inclusion in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- trial group(tolvaptan group) (Type: ACTIVE_COMPARATOR): trial group (tolvaptan 15mg/d po(10 days) + torasemide 20mg/d iv,n=20)
- control group (Type: PLACEBO_COMPARATOR): control group(placebo 15mg/d po(10 days) +torasemide 20mg/d iv,n=20)

Based on this trial design, predict the completion outcome and termination type (if applicable).